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Rezumat
Introducere. Nivelul peptidelor natriuretice, biomarkeri larg utiliza i în diagnosticarea și monitorizarea insuficien ei cardiace, este influen at semnificativ de greutate, fiind mult mai scăzut la subiec ii obezi fa ă de cei normoponderali. Aceasta duce la interpretarea dificilă a informa iilor în practica curentă, în care pacien ii au frecvent IMC >30 kg/m². În aceste condi ii, ar putea fi utilă folosirea unui nou biomarker neinfluen at de greutate în insuficien a cardiacă acut-decompensată (ADHF).
Obiectivul studiului îl reprezintă evaluarea modificărilor CA-125 la pacien ii cu ADHF obezi versus normoponderali.
Material și metodă. 110 bolnavi (vârstă medie 72±10 ani, 63% bărba i) cu ADHF de etiologie ischemică au fost evalua i clinic, ecocardiografic și biologic (NT-proBNP, CA-125).
Rezultate. Valoarea medie a IMC a fost de 27.6±5.8 kg/m², iar 35 (33%) subiec i au fost obezi (IMC >30 kg/m²
Background
Acute decompensated heart failure has an increasing incidence and poor prognosis, being a major cause of death and hospital readmission and requiring urgent optimized therapy .
(
The natriuretic peptides are the most frequently used biomarkers in clinical practice and monitoring the level of BNP and NT-proBNP for diagnosis, prognosis and treatment is recommended in the ESC Guidelines for diagnosis and treatment of heart failure ; but the natriuretic peptides ( ) 2 levels are significantly affected by weight.
The NT-proBNP in obese subjects is much lower than in normal weight subjects, making it difficult to interpret in current practice w h e r e t h e p a t i e n t s a r e f r e q u e n t l y overweighted. In these conditions, a new The aim of the study was to assess the CA-125 changes in ADHF patients.
Method
The study group included 110 patients with ADHF caused by ischemic cardiomyopathy, treated according to ESC guidelines. The 
Results
The baseline characteristics of the study group are presented in table 1. The mean age of the patients was 72±10 years, with male sex predominance -63% of the patients.
There were 35 (33%) subjects with obesity and the mean BMI was 27.6±5.8 kg/m².
The mean LVEF was 37% and the mean NT-proBNP was 4049±2095 pg/mL.
CA-125 at admission was 53±33 U/mL, much higher than the known upper limit of 35 U/mL. There were no differences between CA-125 levels in males and females: 51±32 There was a significant difference between NT-proBNP at admission in obese versus normoponderal patients 3207±1432 pg/mL ( versus 4457±2737 pg/mL (p=0.02)), which was maintained at discharge (1711±816 pg/mL versus 2674±1475 pg/mL (p=0.03)).
In the same time, the CA-125 did not show significant differences between obese and normoponderal subjects at admission (56±29 U/mL versus 51±20 U/mL (p=0.63)) and discharge (36±20 U/mL versus 33±16 U/mL (p=0.56)).
Discussion
CA-125 is a soluble glycoprotein that seems to have a role as biomarker in HF, being secreted by various stimuli such as mechanical stress, oxidative stress or inflammatory stimuli, pathophysiological mechanisms known to be involved in HF. 
Figure 1. Corelation between the CA-125 level (U/mL) and the NT-proBNP level (pg/mL) at admission
Figure 2. Corelation between the CA-125 level (U/mL) and the NT-proBNP level (pg/mL) at discharge
